Form 483

Topix Pharmaceuticals Inc Form 483, 2015-06-15

FDA issued a Form 483 to Topix Pharmaceuticals Inc on 2015-06-15 with 8 public-safe observations.

483· Form 483 issuedHuman Drugs8 observations

Topix Pharmaceuticals Inc · Amityville, United States · Issued June 15, 2015

Overview

  • 8 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

15 Jun 2015
21 CFR 211.110(a)

Control procedures to monitor and validate performance

Cited by Robert C Horan

15 Jun 2015
21 CFR 211.160(b)

Scientifically sound laboratory controls

Cited by Robert C Horan

15 Jun 2015
21 CFR 211.170(b)

Reserve samples identified, representative, stored

Cited by Robert C Horan

15 Jun 2015
21 CFR 211.184(e)

Records of disposition of rejected material

Cited by Robert C Horan

15 Jun 2015
21 CFR 211.194(a)(2)

Statement of methods and data

Cited by Robert C Horan

Inspected site

TPTopix Pharmaceuticals IncAmityville, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.110(a)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.170(b)Cited across public-safe Form 483 observations1x
21 CFR 211.184(e)Cited across public-safe Form 483 observations1x
21 CFR 211.194(a)(2)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.56(a)Cited across public-safe Form 483 observations1x
21 CFR 211.84(c)(2)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 8 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere